IL13 and Alzheimer disease: These findings were supported by prior analyses from clinical studies of dupilumab (anti‐IL‐4Rα) and lebrikizumab (anti‐IL‐13), both demonstrating significant improvements in AD signs and symptoms regardless of type 2 comorbidities [18, 19, 20, 21].